Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v2.4.0.6
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)
Common Stock
Additional Paid-In Capital
Deficit Accumulated During The Development Stage
Stockholders' Equity - TransBiotec Inc.
Noncontrolling Interest
Total
Biginning Balance, Amount at Dec. 31, 2010 $ 93 $ 7,887,288 $ (9,619,537) $ (1,732,156)    $ (1,732,156)
Beginning Balance, Shares at Dec. 31, 2010 9,309,450          
Stock issued for cash, Shares 977,455          
Stock issued for cash, Amount 10 435,990   436,000   436,000
Stock issued for debt retirement, Shares 2,647,477          
Stock issued for debt retirement, Amount 26 1,110,849   1,110,875   1,110,875
Stock issued for reverse acquisition, Shares 1,410,650          
Stock issued for reverse acquisition, Amount 14 (191,095)   (191,081)   (191,081)
Reverse acquisition - net deficit of noncontrolling interest   607,690   607,690 (607,690)   
Fractional shares Paid in capital - beneficial conversion feature, Shares (1,565)          
Fractional shares Paid in capital - beneficial conversion feature, Amount   70,000   70,000   70,000
Share exchange - noncontrolling interest, Shares 11,128,205          
Share exchange - noncontrolling interest, Amount 111 (653,763)   (653,652) 653,652   
Net Loss     (1,101,401) (1,101,401) (80,842) (1,182,243)
Ending Balance, Amount at Dec. 31, 2011 254 9,266,959 (10,720,938) (1,453,725) (34,880) (1,488,605)
Ending Balance, Shares at Dec. 31, 2011 25,471,672          
Stock issued for cash, Shares 326,667          
Stock issued for cash, Amount 3 121,997   122,000   122,000
Share exchange - noncontrolling interest, Shares 251,105          
Share exchange - noncontrolling interest, Amount 3 (16,662)   (16,659) 16,659   
Stock issued for services, Shares 3,805,950          
Stock issued for services, Amount 38 2,321,919   2,321,957   2,321,957
Stock conversion of note payable , Shares 460,160          
Stock conversion of note payable, Amount 5 69,995   70,000   70,000
Paid in capital - beneficial conversion feature   39,929   39,929 207 40,136
Paid in capital - stock option expense   4,042   4,042   4,042
Paid in capital - Equity obligation settlement at fair value   95,100   95,100   95,100
Net Loss     (3,553,306) (3,553,306) (7,615) (3,560,921)
Ending Balance, Amount at Dec. 31, 2012 $ 303 $ 11,903,279 $ (14,274,244) $ (2,370,662) $ (25,629) $ (2,396,291)
Ending Balance, Shares at Dec. 31, 2012 30,315,554